CY1114030T1 - Ομοιογενη παρασκευασματα toy il-29 - Google Patents

Ομοιογενη παρασκευασματα toy il-29

Info

Publication number
CY1114030T1
CY1114030T1 CY20131100436T CY131100436T CY1114030T1 CY 1114030 T1 CY1114030 T1 CY 1114030T1 CY 20131100436 T CY20131100436 T CY 20131100436T CY 131100436 T CY131100436 T CY 131100436T CY 1114030 T1 CY1114030 T1 CY 1114030T1
Authority
CY
Cyprus
Prior art keywords
amino acid
seq
cysteine
toy
acid residues
Prior art date
Application number
CY20131100436T
Other languages
English (en)
Inventor
Lowell J Brady
Kevin M Klucher
Chung Chan
Dennis L Dong
Hong Y Liu
Paul O Sheppard
Thomas R Bukowski
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Publication of CY1114030T1 publication Critical patent/CY1114030T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

Παρέχεται απομονωμένο πολυπεπτίδιο το οποίο αποτελείται από μια αλληλουχία αμινοξέων που έχει τουλάχιστον 90% ταυτότητα αλληλουχίας προς τα υπολείμματα αμινοξέων 1-181 της SEQ ID ΝΟ:4, όπου το υπόλειμμα αμινοξέος που αντιστοιχεί στην κυστεΐνη στη θέση 171 της SEQ ID ΝΟ:4 υποκαθίσταται με ένα άλλο αμινοξύ, όπου τα υπολείμματα αμινοξέων που αντιστοιχούν στην κυστεΐνη στη θέση 15 και στη θέση 112 της SEQ ID ΝΟ:4 σχηματίζουν πρώτο δισουλφιδικό δεσμό, και όπου τα υπολείμματα αμινοξέων που αντιστοιχούν στην κυστεΐνη στη θέση 49 και στη θέση 145 της SEQ ID ΝΟ:4 σχηματίζουν δεύτερο δισουλφιδικό δεσμό, και όπου το πολυπεπτίδιο επάγει την έκφραση Διεγειρόμενων από Ιντερφερόνη Γονιδίων στα ανθρώπινα ηπατοκύτταρα.
CY20131100436T 2003-08-07 2013-05-31 Ομοιογενη παρασκευασματα toy il-29 CY1114030T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49319403P 2003-08-07 2003-08-07
US55184104P 2004-03-10 2004-03-10
US55914204P 2004-04-02 2004-04-02
EP10173335A EP2251353B1 (en) 2003-08-07 2004-08-09 Homogeneous preparations of IL-29

Publications (1)

Publication Number Publication Date
CY1114030T1 true CY1114030T1 (el) 2016-07-27

Family

ID=34279787

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100436T CY1114030T1 (el) 2003-08-07 2013-05-31 Ομοιογενη παρασκευασματα toy il-29

Country Status (16)

Country Link
US (38) US7157559B2 (el)
EP (4) EP1668031B1 (el)
JP (2) JP4808157B2 (el)
CN (1) CN1910200A (el)
AT (1) ATE388963T1 (el)
AU (1) AU2004270652B2 (el)
CA (1) CA2534907C (el)
CY (1) CY1114030T1 (el)
DE (1) DE602004012424T2 (el)
DK (2) DK2251353T3 (el)
ES (2) ES2405209T3 (el)
HK (1) HK1150618A1 (el)
IL (1) IL210381A0 (el)
PL (1) PL2251353T3 (el)
PT (1) PT2251353E (el)
WO (1) WO2005023862A2 (el)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
AU2001271786A1 (en) 2000-06-30 2002-01-14 Zymogenetics Inc. Interferon-like protein zcyto21
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7910313B2 (en) * 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
AU2003286624B2 (en) * 2002-10-23 2008-11-13 Bristol-Myers Squibb Company Methods for treating viral infection using IL-28 and IL-29
ATE479763T1 (de) 2003-04-29 2010-09-15 Avi Biopharma Inc Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen
PT2251353E (pt) 2003-08-07 2013-05-07 Zymogenetics Inc Preparações homogéneas de il-28 e il-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
AU2005231476B2 (en) 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
BRPI0513865A (pt) 2004-07-29 2008-05-20 Zymogenetics Inc métodos para tratar cáncer, para inibir a progressão de cáncer, para retardar o começo de cáncer, para reduzir a severidade de cáncer, e para inibir pelo menos uma das condições ou sintomas de cáncer, do linfoma não-hodgkin, do mieloma múltiplo, e de tumores da cabeça e o pescoço
ES2579758T3 (es) * 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CA2616004A1 (en) * 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
US20070053933A1 (en) * 2005-07-20 2007-03-08 Sheppard Paul O IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME
CA2625208A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
BRPI0817026A2 (pt) * 2007-09-20 2017-05-16 Australian Poultry Crc Pty Ltd molécula de ácido nucleico, polipeptídeo isolado, polipeptídeo de fusão, construção genética, métodos para produzir uma molécula de interferon-lambda recombinante aviário em uma célula, para identificar uma sequência genética de interferon-lambda aviário, para induzir ou regular de modo positivo uma resposta imune em aves e para o tratamento ou profilaxia de aves, molécula de interferon-lambda recombinante aviário, célula isolada, molécula de anticorpo, meio legível por computador, ensaio para mdir o nível de um polipeptídeo de interferon-lambda aviário em aves, uso do polipeptídeo de interferon-lambda aviário ou de uma molécula de ácido nucleico, gênero alimentício medicinal ou terapêutico, adjuvante, e, composição farmacêutica veterinária.
US8354125B2 (en) 2007-10-27 2013-01-15 Grant Gallagher Ex-vivo treatment of peripheral blood leukocytes with IFN-λ
TR201802202T4 (tr) 2007-12-07 2018-03-21 Merck Serono Sa IL-31'e spesifik beşerileştirilmiş antikor molekülleri.
JP5873717B2 (ja) 2008-04-04 2016-03-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｉｌ−２８及び組成物を用いたワクチン及び免疫治療薬並びにその使用方法
JP2011522834A (ja) * 2008-06-05 2011-08-04 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
CA2735006A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
US8363580B2 (en) * 2009-03-31 2013-01-29 Rosemount Inc. Disparate radios in a wireless mesh network
EP2362332A1 (en) 2010-02-26 2011-08-31 Seremfor, S.L.U. Method and system of auto checking personal protective equipment, systems and technical work instructions as regards labour risk prevention
EP2569431B1 (en) * 2010-05-13 2015-09-23 Sarepta Therapeutics, Inc. Methods for identifying compounds which modulate interleukins 17 and 23 signaling activity
WO2012065755A1 (en) * 2010-11-19 2012-05-24 Bavarian Nordic A/S Production of ifn-lambda by b cells
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013029062A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Co., Ltd Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
CN102559737A (zh) * 2011-12-13 2012-07-11 江南大学 一种人白细胞介素29的变异体及其制备方法
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
CA2891974A1 (en) * 2012-11-21 2014-05-30 The Governors Of The University Of Alberta Immunomodulatory peptides and methods of use thereof
US9464321B2 (en) * 2013-03-15 2016-10-11 Medical Diagnostic Laboratories, Llc Methods and reagents that specifically detect, distinguish and quantify IFN-λ2 mRNA from IFN-λ3 mRNA in humans
EP3092248B1 (en) * 2014-01-08 2021-06-23 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN104672318A (zh) * 2014-12-17 2015-06-03 江南大学 一种肽链第43位赖氨酸定点突变为亮氨酸的人白介素-29变异体
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN105037523B (zh) * 2015-06-25 2019-02-19 北京三元基因药业股份有限公司 干扰素突变体及其聚乙二醇衍生物
EP3370723B1 (en) 2015-11-04 2020-12-16 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EA201891469A1 (ru) 2015-12-23 2018-12-28 Дзе Джонс Хопкинс Юниверсити Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний
WO2017143253A1 (en) 2016-02-19 2017-08-24 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection with interferon lambda
CN106047806B (zh) * 2016-08-19 2019-07-16 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的外周血细胞培养基
AU2017336078B2 (en) * 2016-09-30 2022-07-21 The Board Of Trustees Of The Leland Stanford Junior University Variant type III interferons and synthekines
CN107043740A (zh) * 2017-05-10 2017-08-15 浙江美保龙生物技术有限公司 一种mdbk细胞培养液及其制备方法、使用方法
CN107630086B (zh) * 2017-11-13 2020-11-03 吉林大学 一种与hbv感染相关的snp分子标记及其应用
CN108070647B (zh) * 2017-12-25 2021-06-01 吉林大学 与hbv感染相关的基因单体型及其应用
CN108570459B (zh) * 2018-04-10 2022-10-04 南京农业大学 一种高效发酵生产重组细菌漆酶的方法
EP4100047A4 (en) * 2020-02-06 2024-03-13 Eiger Biopharmaceuticals Inc TREATING CORONAVIRUS INFECTION WITH INTERFERON LAMBDA
WO2021178612A1 (en) 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CA3185614A1 (en) 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
CN116219078B (zh) * 2023-05-08 2023-07-11 上海惠盾因泰生物科技有限公司 一种il-29生物学活性测定方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US485332A (en) * 1892-11-01 Wagon-brake
PT72322B (en) 1980-01-08 1982-09-23 Biogen Nv Process for preparation of recombinant dna molecules and of polipeptides similar to human interferon
AU560472B2 (en) 1981-08-25 1987-04-09 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
KR100289201B1 (ko) 1994-02-14 2001-05-02 엘. 데이예를 카렌. 조혈 단백질과 그것의 제조를 위한 재료 및 방법
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US6001597A (en) 1995-11-09 1999-12-14 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5965389A (en) 1995-11-09 1999-10-12 Zymogenetics, Inc. Production of GAD65 in methylotrophic yeast
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU2871899A (en) 1998-03-09 1999-09-27 Schering Corporation Human receptor proteins; related reagents and methods
WO2000055324A1 (en) 1999-03-18 2000-09-21 Zymogenetics, Inc. Murine interferon-alpha named also zcyto13
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US6376585B1 (en) 2000-06-26 2002-04-23 Apex Advanced Technologies, Llc Binder system and method for particulate material with debind rate control additive
AU2001271786A1 (en) 2000-06-30 2002-01-14 Zymogenetics Inc. Interferon-like protein zcyto21
AU2001271589A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
CN1452633A (zh) 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
AU2002241533A1 (en) 2000-11-28 2002-06-11 Zymogenetics Inc. Cytonkine receptor zcytor19
JP2002308030A (ja) * 2001-04-16 2002-10-23 Yazaki Corp 車両用周辺監視装置
EP1501936B1 (en) * 2001-04-20 2008-08-06 ZymoGenetics, Inc. Cytokine protein family
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US20030104579A1 (en) 2001-05-10 2003-06-05 Baum Peter R. Cytokine polypeptides
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7820793B2 (en) 2002-02-08 2010-10-26 University Of Medicine And Dentistry Of New Jersey IFN-λ polypeptides and compositions
AU2003225055B2 (en) 2002-04-19 2009-04-23 Bristol-Myers Squibb Company Cytokine receptor
AU2003286624B2 (en) * 2002-10-23 2008-11-13 Bristol-Myers Squibb Company Methods for treating viral infection using IL-28 and IL-29
US7259969B2 (en) * 2003-02-26 2007-08-21 Wavezero, Inc. Methods and devices for connecting and grounding an EMI shield to a printed circuit board
PT2251353E (pt) * 2003-08-07 2013-05-07 Zymogenetics Inc Preparações homogéneas de il-28 e il-29
US7208541B2 (en) * 2003-08-22 2007-04-24 National Starch And Chemical Investment Holding Corporation Hot melt adhesive
AU2005231476B2 (en) 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
JP4468734B2 (ja) * 2004-04-27 2010-05-26 オリンパス株式会社 映像信号処理装置と映像信号処理プログラム
BRPI0513865A (pt) 2004-07-29 2008-05-20 Zymogenetics Inc métodos para tratar cáncer, para inibir a progressão de cáncer, para retardar o começo de cáncer, para reduzir a severidade de cáncer, e para inibir pelo menos uma das condições ou sintomas de cáncer, do linfoma não-hodgkin, do mieloma múltiplo, e de tumores da cabeça e o pescoço
CN1305902C (zh) 2004-11-25 2007-03-21 汕头大学医学院 一种人白细胞介素29的生产方法及重组il－29工程菌
CA2616004A1 (en) 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
US20070053933A1 (en) * 2005-07-20 2007-03-08 Sheppard Paul O IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME
DE102005000107B4 (de) * 2005-08-25 2014-03-13 Hilti Aktiengesellschaft Pneumatisch betriebenes Setzgerät
CA2625208A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
JP2011522834A (ja) 2008-06-05 2011-08-04 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用

Also Published As

Publication number Publication date
WO2005023862A2 (en) 2005-03-17
US7595174B2 (en) 2009-09-29
US20070054375A1 (en) 2007-03-08
US7629148B2 (en) 2009-12-08
US20170209542A1 (en) 2017-07-27
US20070053875A1 (en) 2007-03-08
US20070055051A1 (en) 2007-03-08
US7485701B2 (en) 2009-02-03
DE602004012424T2 (de) 2009-04-30
EP2251352A1 (en) 2010-11-17
US20070154446A1 (en) 2007-07-05
US7582450B2 (en) 2009-09-01
ES2405209T3 (es) 2013-05-30
US7662589B2 (en) 2010-02-16
JP2007528719A (ja) 2007-10-18
US20070048277A1 (en) 2007-03-01
US20070166282A1 (en) 2007-07-19
CA2534907C (en) 2014-04-29
JP4808157B2 (ja) 2011-11-02
US20070041936A1 (en) 2007-02-22
US7514536B2 (en) 2009-04-07
US20070117967A1 (en) 2007-05-24
US7608428B2 (en) 2009-10-27
US20070042469A1 (en) 2007-02-22
US20050037012A1 (en) 2005-02-17
US20070054374A1 (en) 2007-03-08
US20070055053A1 (en) 2007-03-08
US20070042471A1 (en) 2007-02-22
US7479542B2 (en) 2009-01-20
US20140178333A1 (en) 2014-06-26
US8734776B2 (en) 2014-05-27
US20070043210A1 (en) 2007-02-22
CA2534907A1 (en) 2005-03-17
US20120004161A1 (en) 2012-01-05
PT2251353E (pt) 2013-05-07
US7495077B2 (en) 2009-02-24
US7662590B2 (en) 2010-02-16
US20070055052A1 (en) 2007-03-08
DK1668031T3 (da) 2008-06-30
EP1668031A2 (en) 2006-06-14
US20070042470A1 (en) 2007-02-22
US7157559B2 (en) 2007-01-02
HK1150618A1 (en) 2012-01-06
AU2004270652A1 (en) 2005-03-17
US7517961B2 (en) 2009-04-14
PL2251353T3 (pl) 2013-08-30
US20100104531A1 (en) 2010-04-29
US7629149B2 (en) 2009-12-08
ES2303132T3 (es) 2008-08-01
ATE388963T1 (de) 2008-03-15
JP2011200252A (ja) 2011-10-13
US7485702B2 (en) 2009-02-03
WO2005023862A9 (en) 2006-06-08
CN1910200A (zh) 2007-02-07
US7544779B2 (en) 2009-06-09
US20070055054A1 (en) 2007-03-08
US7727518B2 (en) 2010-06-01
US8343476B2 (en) 2013-01-01
IL210381A0 (en) 2011-03-31
US20070065406A1 (en) 2007-03-22
US20070048276A1 (en) 2007-03-01
US20070048843A1 (en) 2007-03-01
US7588918B2 (en) 2009-09-15
US20080279816A1 (en) 2008-11-13
US20070048844A1 (en) 2007-03-01
US20070054377A1 (en) 2007-03-08
US20070054376A1 (en) 2007-03-08
US20070073044A1 (en) 2007-03-29
US20070059313A1 (en) 2007-03-15
US20070066810A1 (en) 2007-03-22
AU2004270652B2 (en) 2010-06-03
US20070059804A1 (en) 2007-03-15
US20070048274A1 (en) 2007-03-01
US7495078B2 (en) 2009-02-24
US7588919B2 (en) 2009-09-15
US7608427B2 (en) 2009-10-27
US9499598B2 (en) 2016-11-22
EP1927600A1 (en) 2008-06-04
US7495079B2 (en) 2009-02-24
EP2251353B1 (en) 2013-03-06
US20130089517A1 (en) 2013-04-11
US20070041975A1 (en) 2007-02-22
US7638305B2 (en) 2009-12-29
US20070049737A1 (en) 2007-03-01
EP2251353A1 (en) 2010-11-17
US20070048275A1 (en) 2007-03-01
DE602004012424D1 (de) 2008-04-24
US20070172923A1 (en) 2007-07-26
EP1668031B1 (en) 2008-03-12
US7468423B2 (en) 2008-12-23
WO2005023862A3 (en) 2005-06-16
DK2251353T3 (da) 2013-06-03

Similar Documents

Publication Publication Date Title
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
UA93349C2 (ru) Способ стабилизации мономерного белка интерферона
DE60135393D1 (de) Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
HUP0303534A2 (hu) Csökkent immunogenitású módosított interferon-béta
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
ATE403726T1 (de) Cytokin-proteinfamilie
DE59108947D1 (de) Neues menschliches, rekombinantes interferon gamma
LV11816A (lv) Implantejama zalu forma
BRPI0517697A (pt) interferon-beta deamidado
NO914724L (no) Somatotropiner med forandringer i alfa-spiral-1-omraadet ogkombinasjoner med andre mutasjoner
TW200722104A (en) Low-toxicity, long-circulating human interferon-α analogs
EP1557466A4 (en) TUMOR ANTIGEN PROTEIN AND USE THEREOF
ES2033212A6 (es) Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados.
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
DE60041075D1 (de) Antigene modifikation von polypeptiden
ATE347899T1 (de) Interferon nachahmende peptide und rekombinante proteine
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus